Fundraising FoxWinklevoss Capital — 2022 Investments
5 investments dated 2022 · listed companies and verified rows first · show all
Praxis Precision Medicines is a central nervous system precision neuroscience biopharmaceutical company developing therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance, with a pipeline spanning movement disorders and epilepsy.
BiotechDeep TechHealthtechBoston, US
Steve Petrou(Co-Founder, President of Research & Development)inKiran Reddy(Executive Officer, Director)inMarcio Souza(President & Chief Executive Officer)in
BoardNicholas G. Galakatos(Director)in
Co-investorsAvoro Capital AdvisorsCapria VenturesOCV PartnersAlameda ResearchAPOLLO PROJECTSBlackstone+6 more
Flux Marine designs and manufactures all-electric outboard motors and electric propulsion systems for boats, selling to companies and individual customers.
CleantechHardwareMobility & TransportationEast Greenwich, US
Jonathan Lord(Cofounder)Ben Sorkin(Founder)inDaylin Frantin(Co-founder)
Co-investorsNextFab VenturesSlater Technology FundBoost VCCollide Capital
Praxis offers an alternative to traditional college for eligible U.S. citizens, providing a program focused on self-direction, practical job skills, and a supported job search with a job-offer guarantee.
EdTechFuture of Work
Co-investorsService Provider CapitalAlameda ResearchAPOLLO PROJECTSFirework VenturesNorwest Venture PartnersParadigm Capital+5 more
Volopay provides corporate cards, automated expense management, and accounting integrations for businesses.
Enterprise SoftwareFintechSaaSBengaluru, IN
Rajith Shaji(Founder)inRajesh Raikwar(Founder)inRajith Shaji 🤝(Founder)inRajesh Raikwar Rajith Shaji(Founder)Rajith Shaji Rajesh Raikwar(Founder)Neha Verma(HR)
Co-investorsAccial CapitalAntlerCP VenturesKube VCSoma CapitalSprint Vc+6 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.